Introducing Melanoma Institute Australia's Conjoint Medical Directors
14 March 2017
Two of the world’s best minds in melanoma have taken over the academic and clinical leadership of Melanoma Institute Australia (MIA). Professor Georgina Long and Professor Richard Scolyer are the new Conjoint Medical Directors of MIA, and are shaping the future direction of melanoma research, treatment and education.
Professor Long is a world-renowned clinical medical oncologist and melanoma researcher who is also President Elect for the prestigious international Society for Melanoma Research. She leads an extensive clinical trials team and research laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma.
Professor Scolyer is a world- leading surgical pathologist and melanoma researcher who has authored more than 450 seminal publications on this disease. Professor Scolyer’s expertise has already delivered exponential improvements in diagnosis and the staging of melanoma which determines a patient’s treatment pathway.
Together with their colleagues at MIA, they are changing the face of melanoma diagnosis and treatment in Australia and around the world.
‘Quite simply, I want to make a difference,” Professor Long said. ‘’I’d love to eradicate melanoma and put ourselves out of a job. That is the ultimate goal.”
‘Even if we haven’t eradicated melanoma in the next five years, I’d like to think we can control it long term so people don’t die of this disease,” Professor Scolyer added.
Sharing the Medical Director role means double the expertise and double the perspective on challenges. Both Professors believe their partnership will be crucial to leading Melanoma Institute Australia towards breaking new ground in melanoma diagnosis and treatment.
‘We know that ultimately prevention is better than cure, so we have to attack the disease at different levels from education, prevention, screening, early diagnosis, and by providing the best early treatment for the best outcomes,’ Professor Scolyer said.
‘The key to tackling melanoma is definitely collaboration, communication and sharing knowledge,” Professor Long added.
Melanoma Institute Australia is the leading centre in the world with a single focus on melanoma care, research and education.
An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.